Cisplatin nephrotoxicity: A review

American Journal of the Medical Sciences

Volumn 334, Issue 2, 2007, Pages 115-124

  Yao, Xin ^a   Panichpisal, Kessarin ^a   Kurtzman, Neil ^a   Nugent, Kenneth ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Acute renal insufficiency; Apoptosis; Cisplatin; Reactive oxygen species; Toxicity

Indexed keywords

ALLOPURINOL; AMIFOSTINE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CISPLATIN; EBSELEN; MAGNESIUM; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM; PROCAINAMIDE; REACTIVE OXYGEN METABOLITE; SALICYLIC ACID DERIVATIVE; SODIUM;

APOPTOSIS; BREAST METASTASIS; CEREBROVASCULAR ACCIDENT; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; FIBROGENESIS; GENE CONTROL; GLOMERULUS FILTRATION; HUMAN; KIDNEY INJURY; KIDNEY TUBULE CELL; KIDNEY TUBULE DISORDER; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PROPHYLAXIS; REVIEW; SALURESIS; SIGNAL TRANSDUCTION; WASTING SYNDROME;

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; KIDNEY; RENAL INSUFFICIENCY;

EID: 34547891848     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31812dfe1e     Document Type: Review

References (84)

1. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.
2. Schrier RW, Wang W, Poole B, et al. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004;114:5-14.
3. Merouani A, Shpall EJ, Jones RB, et al. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 1996;50:1026-31.
4. Kuhlmann MK, Burkhardt G, Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997;12:2478-80.
5. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-4.
6. Kroning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol 2000;45:43-9.
7. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993;67:1171-6.
8. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167:1477-84.
9. Ludwig T, Riethmuller C, Gekle M, et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004;66:196-202.
10. Thomas MC, Tikellis C, Kantharidis P, et al. The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. J Pharmacol Exp Ther 2004;311:456-66.
11. Holzer AK, Samimi G, Katano K, et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 2004;66:817-23.
12. Townsend DM, Deng M, Zhang L, et al. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1-10.
13. Townsend DM, Hanigan MH. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 2002;300:142-8.
14. Nelson JA, Pan BF, Swanson DA, et al. Cysteine conjugate beta-lyase activity in human renal carcinomas. Cancer Biochem Biophys 1995;14:257-63.
15. Ekborn A, Lindberg A, Laurell G, et al. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 2003;51:36-42.
16. Huang Q, Dunn II, RT Jayadev S, et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 2001;63:196-207.
17. Leussink BT, Baelde HJ, Broekhuizen-van den Berg TM, et al. Renal epithelial gene expression profile and bismuth-induced resistance against cisplatin nephrotoxicity. Hum Exp Toxicol 2003;22:535-40.
18. Thompson KL, Afshari CA, Amin RP, et al. Identification of platform-independent gene expression markers of cisplatin nephrotoxicity. Environ Health Perspect 2004;112:488-94.
19. Arany I, Megyesi JK, Kaneto H, et al. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 2004;287:F543-9.
20. Jo SK, Cho WY, Sung SA, et al. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 2005;67:458-66.
21. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005;289:F166-74.
22. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996;270:F700-8.
23. Kawai Y, Nakao T, Kunimura N, et al. Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J Pharmacol Sci 2006;100:65-72.
24. Yilmaz HR, Iraz M, Sogut S, et al. The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. Pharmacol Res 2004;50:287-90.
25. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001;12:2683-90.
26. Kadikoylu G, Bolaman Z, Demir S, et al. The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 2004;23:29-34.
27. Shino Y, Itoh Y, Kubota T, et al. Role of poly(ADP-ribose-) polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Radic Biol Med 2003;35:966-77.
28. Badary OA, Abdel-Maksoud S, Ahmed WA, et al. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 2005;76:2125-35.
29. Durak I, Ozbek H, Karaayvaz M, et al. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity. Drug Chem Toxicol 2002;25:1-8.
30. Sener G, Satiroglu H, Kabasakal L, et al. The protective effect of melatonin on cisplatin nephrotoxicity. Fundam Clin Pharmacol 2000;14:553-60.
31. Weijl NI, Elsendoorn TJ, Lentjes EG, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 2004;40:1713-23.
32. Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 2004;4:20.
33. Yildirim Z, Sogut S, Odaci E, et al. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 2003;47:149-56.
34. Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985;249:F490-6.
35. Tanaka T, Kojima I, Ohse T, et al. Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2005;289:F1123-33.
36. Kaushal GP, Kaushal V, Hong X, et al. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 2001;60:1726-36.
37. Tsuruya K, Ninomiya T, Tokumoto M, et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003;63:72-82.
38. Dimanche-Boitrel MT, Meurette O, Rebillard A, et al. Role of early plasma membrane events in chemotherapy-induced cell death. Drug Resist Updat 2005;8:5-14.
39. Faubel S, Ljubanovic D, Reznikov L, et al. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 2004;66:2202-13.
40. Basnakian AG, Apostolov EO, Yin X, et al. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol 2005;16:697-702.
41. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 2004;65:490-9.
42. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-42.
43. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003;285:F610-8.
44. Yamate J, Sato K, Ide M, et al. Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet Pathol 2002;39:322-33.
45. Guinee DG Jr, van Zee B, Houghton DC. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer 1993;71:4050-4.
46. Robbins ME, Bywaters TB, Jaenke RS, et al. Long-term studies of cisplatin-induced reductions in porcine renal functional reserve. Cancer Chemother Pharmacol 1992;29:309-15.
47. Yamate J, Machida Y, Ide M, et al. Effects of lipopolysaccharide on the appearance of macrophage populations and fibrogenesis in cisplatin-induced rat renal injury. Exp Toxicol Pathol 2004;56:13-24.
48. Hellwig-Burgel T, Stiehl DP, Wagner AE, et al. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res 2005;25:297-310.
49. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 1993;50:147-58.
50. Isnard-Bagnis CDG. Anticancer drugs. In: De Broe M.E PGA, Bennett W.M, Verpooten G.A, ed. Clinical Nephrotoxins (ed 2nd): Kluwer Academic; 2003:353-72.
51. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity: a review. Cancer Chemother Pharmacol 1989;25:1-9.
52. Kollmannsberger C, Kuzcyk M, Mayer F, et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999;17:275-81.
53. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993;27:1519-25.
54. Lajer H, Kristensen M, Hansen HH, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005;56:535-42.
55. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38.
56. Meyer KB, Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab 1994;20:201-13.
57. Goren MP. Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Med Pediatr Oncol 2003;41:186-9.
58. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999;25:47-58.
59. Vickers AE, Rose K, Fisher R, et al. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 2004;32:577-90.
60. Tanaka H, Ishikawa E, Teshima S, et al. Histopathological study of human cisplatin nephropathy. Toxicol Pathol 1986;14:247-57.
61. Portilla D, Li S, Nagothu KK, et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 2006;69:2194-204.
62. Santoso JT, Lucci JA III, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003;52:13-8.
63. Dumas M, de Gislain C, d'Athis P, et al. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol. 1990;26:278-82.
64. Daley-Yates PT, McBrien DC. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem Pharmacol 1985;34:2363-9.
65. Hanigan MH, Deng M, Zhang L, et al. Stress response inhibits the nephrotoxicity of cisplatin. Am J Physiol Renal Physiol 2005;288:F125-32.
66. Fu S, Kavanagh JJ, Hu W, et al. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:1717-32.
67. Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 2001;12:1195-203.
68. Grover B, Auberger C, Sarangarajan R, et al. Functional impairment of renal organic cation transport in experimental diabetes. Pharmacol Toxicol 2002;90:181-6.
69. Sarangarajan R, Cacini W. Early onset of cisplatin-induced nephrotoxicity in streptozotocin-diabetic rats treated with insulin. Basic Clin Pharmacol Toxicol 2004;95:66-71.
70. Esposito M, Viale M, Vannozzi MO, et al. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Toxicol Appl Pharmacol 1996;140:370-7.
71. Viale M, Vannozzi MO, Pastrone I, et al. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? J Pharmacol Exp Ther 2000;293:829-36.
72. Lynch ED, Gu R, Pierce C, et al. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 2005;201:81-9.
73. Nisar S, Feinfeld DA. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Ren Fail 2002;24:529-33.
74. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med 2005;2:383-6.
75. Jones MM, Basinger MA, Holscher MA. Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundam Appl Toxicol 1992;18:181-8.
76. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999;26:72-81.
77. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165-7.
78. Treskes M, van der Vijgh WJ. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol 1993;33:93-106.
79. Kohda Y, Kawai Y, Iwamoto N, et al. Serum thymic factor, FTS, attenuates cisplatin nephrotoxicity by suppressing cisplatin-induced ERK activation. Biochem Pharmacol 2005;70:1408-16.
80. Schweyer S, Soruri A, Meschter O, et al. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer 2004;91:589-98.
81. Li G, Sha SH, Zotova E, et al. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 2002;82:585-96.
82. Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001;60:2118-28.
83. Nagothu KK, Bhatt R, Kaushal GP, et al. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005;68:2680-93.
84. Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 1986;54:19-23.